Salarius Pharmaceuticals Announces Reverse Stock Split

Salarius Pharmaceuticals ( (SLRX) ) just unveiled an announcement.

On August 15, 2025, Salarius Pharmaceuticals filed a Certificate of Amendment to implement a 1-for-15 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time. This move, approved by stockholders on July 8, 2025, aims to help the company regain compliance with Nasdaq’s $1.00 minimum closing bid price requirement. The reverse split will reduce the number of outstanding shares from approximately 7.6 million to 509,000 and will affect all stockholders uniformly, with cash provided in lieu of fractional shares. Trading on a split-adjusted basis will begin on August 18, 2025, under a new CUSIP number.

Spark’s Take on SLRX Stock

According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.

Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.

To see Spark’s full report on SLRX stock, click here.

More about Salarius Pharmaceuticals

Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies using protein inhibition and degradation. The company has two drug candidates, including seclidemstat, which is in a Phase 1/2 clinical study for hematologic cancers, and SP-3164, an oral small molecule protein degrader.

Average Trading Volume: 3,217,377

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.46M

Find detailed analytics on SLRX stock on TipRanks’ Stock Analysis page.